EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Evaluation of a Multiplex Electrochemiluminescence Assay for Detection of Anti-Pneumococcal Antibodies in the Diagnosis of Selective Polysaccharide Antibody Deficiency

Nicolas Perrard, Aurore Collet, Sarah Stabler, Sandrine Poizot, Myriam Labalette, Gatien Durand, Frédéric Batteux, Floriane Mirgot, Benjamin Lopez, Sylvain Dubucquoi, Lucie Chevrier, Guillaume Lefèvre

Journal of Clinical Immunology · 2025

DOI: 10.1007/s10875-025-01911-0 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Nicolas Perrard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Clinical Immunology, CHU Lille, Lille, F-59000, France. Nicolas.perrard@chu-lille.fr. Hauptthemen laut MEDLINE: Antibodies, Bacterial, Streptococcus pneumoniae, Luminescent Measurements, Pneumococcal Infections. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre Hospitalier Universitaire de Lille.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptococcus pneumoniae can be responsible for severe infections, especially in patients with primary antibody deficiencies like selective anti-polysaccharide antibodies deficiency (SPAD). The reference method recommaned by the World Health Organization for assessment of anti-pneumococcal capsular polysaccharides (PCPs) IgG antibodies is a standardized serotype-specific ELISA (WHO-SSA), but this manual method is time-consuming and limit the number of evaluated PCPs. We aim to evaluate the performance values of a multiplex assay based on electrochemiluminescence (ECL-plex). A panel of 164 sera from 82 patients sampled before and 4–8 weeks after immunization by the 23-valent pneumococcal polysaccharide vaccine (PPV23) were assessed by the reference WHO-SSA (7 to 13 serotypes) and by an 18-plex ECL assay (18 serotypes). All patients had normal serum Ig/subclasses levels and were classified as good ( n = 43) or poor responders ( n = 39, i.e. SPAD patients) according to the American Academy of Asthma, Allergy and Immunology’s (AAAAI) current guidelines. We observed excellent correlations between the two methods for anti-PCPs titers against 7 serotypes ( r = 0.88 [95% CI: 0.87–0.90], n = 124 sera) and 13 serotypes ( r = 0.87 [0.87–0.89], n = 40 sera). Using the AAAAI’s guidelines for interpretation, the test performance of the 18-plex ECL assay for SPAD diagnosis showed a sensitivity of 95% and specificity of 84%, positive and negative predictive values of 84% and 95%, respectively. The percentage of agreement was 89% between the SSA and the 18-plex ECL assay. The 18-plex ECL assay is a reliable, rapid, and simple method for evaluating anti-PCPs response and screening for SPAD diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BacterialStreptococcus pneumoniaeLuminescent MeasurementsPneumococcal InfectionsPolysaccharides, BacterialImmunologic Deficiency SyndromesHumansMaleFemaleAdultPneumococcal VaccinesMiddle AgedAdolescentImmunoglobulin GChildYoung AdultAgedSensitivity and SpecificityElectrochemical TechniquesChild, Preschool

Stichwörter der Autor:innen

ECLElectrochemiluminescenceEncapsulated bacterial infectionsPrimary immunodeficiencySelective anti-polysaccharide antibody deficiencySpecific antibody deficiency

Substanzen

Antibodies, BacterialPneumococcal Vaccines23-valent pneumococcal capsular polysaccharide vaccineImmunoglobulin GPolysaccharides, Bacterial

Autor:innen und Institutionen

  • Department of Internal Medicine and Clinical Immunology, CHU Lille, Lille, F-59000, France. Nicolas.perrard@chu-lille.fr.
  • Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, F-59000, France. Nicolas.perrard@chu-lille.fr.
  • Institute of Immunology, CHU Lille, Lille, F-59000, France. Nicolas.perrard@chu-lille.fr.
  • Regional Center for Primary Immune Deficiency, CEREDIH Lille, CHU Lille, Lille, F-59000, France. Nicolas.perrard@chu-lille.fr.
  • Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, F-59000, France.
  • Institute of Immunology, CHU Lille, Lille, F-59000, France.

Förderung

  • Centre Hospitalier Universitaire de Lille

Zitieren

APA

Perrard, N., Collet, A., Stabler, S., Poizot, S., Labalette, M., Durand, G., Batteux, F., Mirgot, F., Lopez, B., Dubucquoi, S., Chevrier, L., & Lefèvre, G. (2025). Evaluation of a Multiplex Electrochemiluminescence Assay for Detection of Anti-Pneumococcal Antibodies in the Diagnosis of Selective Polysaccharide Antibody Deficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-025-01911-0

Vancouver

Perrard N, Collet A, Stabler S, Poizot S, Labalette M, Durand G, et al. Evaluation of a Multiplex Electrochemiluminescence Assay for Detection of Anti-Pneumococcal Antibodies in the Diagnosis of Selective Polysaccharide Antibody Deficiency. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-025-01911-0

BibTeX
@article{Perrard2025,
  author = {Perrard, Nicolas and Collet, Aurore and Stabler, Sarah and Poizot, Sandrine and Labalette, Myriam and Durand, Gatien and Batteux, Frédéric and Mirgot, Floriane and Lopez, Benjamin and Dubucquoi, Sylvain and Chevrier, Lucie and Lefèvre, Guillaume},
  title = {Evaluation of a Multiplex Electrochemiluminescence Assay for Detection of Anti-Pneumococcal Antibodies in the Diagnosis of Selective Polysaccharide Antibody Deficiency},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  doi = {10.1007/s10875-025-01911-0}
}
Kostenlos starten →